Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Raw Materials (2023 - 2025)

Historic Raw Materials for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $2.5 million.

  • Tonix Pharmaceuticals Holding's Raw Materials fell 2582.19% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 2582.19%. This contributed to the annual value of $3.1 million for FY2024, which is 1495.43% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Raw Materials stood at $2.5 million for Q3 2025, which was down 2582.19% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Raw Materials registered a high of $3.6 million during Q4 2023, and its lowest value of $2.3 million during Q2 2025.
  • Its 3-year average for Raw Materials is $2.9 million, with a median of $2.9 million in 2024.
  • Per our database at Business Quant, Tonix Pharmaceuticals Holding's Raw Materials tumbled by 1495.43% in 2024 and then tumbled by 2582.19% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Raw Materials (Quarter) stood at $3.6 million in 2023, then fell by 14.95% to $3.1 million in 2024, then dropped by 19.18% to $2.5 million in 2025.
  • Its Raw Materials was $2.5 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.7 million in Q1 2025.